跳至主要内容
临床试验/CTRI/2022/01/039227
CTRI/2022/01/039227已完成未知

Efficacy of Nicorandil as an add-on therapy to standard treatment in acute ischemic stroke- A Randomized, single blind, controlled clinical trial - ENCORE

SRMIST0 个研究点目标入组 19 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
19

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age 18 -75 years.
  • -Both genders.
  • -Diagnosis of acute ischemic stroke.
  • -More than 24 hours of onset of symptoms and not greater than 96 hours.
  • -Modified Rankin scale greater than two.
  • -Ability to ingest oral medication.
  • -BMI >18.5 kg /m².

排除标准

  • Haemorrhagic stroke.
  • Hypotension with a SBP < 100 mmHg.
  • Patients on ACEIs and ARBs.
  • Patients on steroids.
  • Patients with respiratory compromise.
  • Patients on antidepressant drugs.
  • Severe acid peptic disease.
  • Kidney dysfunction (GFR < 30ml /min).
  • Intake of NSAID (exemption of Paracetamol).
  • Severe unstable medical illnesses, including uncontrolled cardiac conditions or heart failure, cardiogenic shock (New York Heart Association Class III or IV).
  • Use of any investigational agents within 30 days prior to screening.
  • Pregnant women and lactating mothers.
  • Severe hypovolemia.
  • Severe liver dysfunction.
  • Severe bradycardia ( <50 bpm).
  • Patients with G6PD deficiency.
  • Clotting factor Deficiency

研究者

发起方
SRMIST

相似试验